The revised american thyroid association management guidelines 2009 for patients with differentiated thyroid cancer: An evidence-based risk-adapted approach

Clinical Oncology

Volumn 22, Issue 6, 2010, Pages 472-474

  Mallick, U K ^a  

^a FREEMAN HOSPITAL   (United Kingdom)

Author keywords

DTC guidelines ATA 2009; Evidence based recommendation; Further research; Risk adapted treatment; Risk stratification

Indexed keywords

RADIOACTIVE IODINE; THYROGLOBULIN;

ARTICLE; CANCER SURGERY; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIATED THYROID CANCER; DOSIMETRY; EVIDENCE BASED PRACTICE; INTRATHYROIDAL PAPILLARY CARCINOMA; LOBECTOMY; MEDICAL DECISION MAKING; MEDICAL SOCIETY; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RADIATION EXPOSURE; RISK ASSESSMENT; THYROID CANCER; THYROID NODULE; THYROIDECTOMY; EVIDENCE BASED MEDICINE; HUMAN; PATHOLOGY; THYROID NEOPLASMS; UNITED STATES;

AMERICAN MEDICAL ASSOCIATION; EVIDENCE-BASED MEDICINE; HUMANS; RISK ADJUSTMENT; THYROID NEOPLASMS; UNITED STATES;

EID: 77954761154     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2010.05.001     Document Type: Article

References (10)

1. Cooper D.S., Doherty G.M., Haughen B.R., et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009, 19:1167-1214.
2. Wartofsky L. Highlights of the American Thyroid Association guidelines for patients with thyroid nodules or differentiate thyroid carcinoma: 2009 revision. Thyroid 2009, 19:1139-1143.
3. Mazzaferri E.L. What is the optimal initial treatment of low-risk papillary thyroid cancer (and why is it controversial)?. Oncology (Williston Park) 2009, 23:579-588.
4. Hay I.D. Managing patients with a preoperative diagnosis of AJCC/UICC stage I (T1N0M0) papillary thyroid carcinoma: east versus west, whose policy is best?. World J Surg 2010, 34(6):1291-1293.
5. Puxeddu E., Filetti S. The 2009 American Thyroid Association guidelines for management of thyroid nodules and differentiated thyroid cancer: progress on the road from consensus to evidence based practice. Thyroid 2009, 19:1145-1147.
6. Thyroid Cancer Guidelines Update Group, Perros P. Guidelines for the management of thyroid cancer 2007 2007, British Thyroid Association, Royal College of Physicians, London. 2nd ed.
7. Mazzaferri E.L., Doherty G.M., Steward D.L. The pros and cons of prophylactic central compartment lymph node dissection for papillary thyroid carcinoma. Thyroid 2009, 19:683-689.
8. Barbaro D., Verburg F.A., Luster M., Reiners C., Rubello D. ALARA in rhTSH-stimulated post-surgical thyroid remnant ablation: what is the lowest reasonably achievable activity?. Eur J Nucl Med Mol Imaging 2010 Mar 20, [Epub ahead of print].
9. Mallick U., Harmer C., Hackshaw A. The HiLo trial: a multicentre randomised trial of high- versus low-dose radioiodine, with or without recombinant human thyroid stimulating hormone, for remnant ablation after surgery for differentiated thyroid cancer. Clin Oncol (R Coll Radiol) 2008, 20:325-326.
10. Chao, M. Management of differentiated thyroid cancer with rising thyroglobulin and negative diagnostic radioiodine whole body scan. Clin Oncol 2010, in this issue, doi:10.1016/j.clon.2010.05.005.